Here are five things to know:
1. The company is planning to create a new drug pipeline, and its R&D efforts will be focused in Japan and the United States.
2. Takeda will also focus its efforts in three primary therapeutic areas — oncology, gastroenterology and the central nervous system.
3. The company is considering shutting down some of its United Kingdom operations.
4. Job cuts are expected, noted Takeda’s chief medical and scientific officer.
5. The number of jobs that are impacted could vary based on the progress of the overhaul.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: July 18 — 22
Schizophrenic son of gastroenterologist Dr. William Wu found guilty of stabbing him: 5 notes
LifeBond’s surgical sealant kit receives FDA IDE approval: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.